siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 290, Issue 2, 2006, Pages

  Miyawaki Shimizu, Kayo ^a   Predescu, Dan ^a   Shimizu, Jun ^a   Broman, Michael ^a   Predescu, Sanda ^a   Malik, Asrar B ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Caveolae; Interendothelial junction; Nitric oxide

Indexed keywords

ALBUMIN; CAVEOLIN 1; LIPOSOME; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; CAVEOLA; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG BLOOD VESSEL; LUNG CAPILLARY; LUNG ENDOTHELIUM; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; BLOOD; CAPILLARY PERMEABILITY; DRUG EFFECT; GENETICS; LUNG; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; CAPILLARY PERMEABILITY; CAVEOLAE; CAVEOLIN 1; LUNG; MALE; MICE; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RNA, SMALL INTERFERING;

EID: 33644839698     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00292.2005     Document Type: Article

References (53)

1. Anderson RG. The caveolae membrane system. Annu Rev Biochem 67: 199-225, 1998.
2. Anderson RG, Kamen BA, Rothberg KG, and Lacey SW. Potocytosis: sequestration and transport of small molecules by caveolae. Science 255: 410-411, 1992.
3. Bauer PM, Yu J, Chen Y, Hickey R, Bernatchez PN, Looft-Wilson R, Huang Y, Giordano F, Stan RV, and Sessa WC. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci USA 102: 204-209, 2005.
4. Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P, and Sessa WC. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci USA 102: 761-766, 2005.
5. Bist A, Fielding PE, and Fielding CJ. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci USA 94: 10693-10698, 1997.
6. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, and Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362-1367, 2000.
7. Cohen AW, Hnasko R, Schubert W, and Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341-1379, 2004.
8. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, and Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284: C457-C474, 2003.
9. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, and Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222-C235, 2003.
10. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, and Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
11. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
12. Elbashir SM, Lendeckel W, and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200, 2001.
13. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, and Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 20: 6877-6888, 2001.
14. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, and Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 272: 16374-16381, 1997.
15. Farquhar MG and Palade GE. Junctional complexes in various epithelia. J Cell Biol 17: 375-412, 1963.
16. Feron O and Kelly RA. The caveolar paradox: suppressing, inducing, and terminating eNOS signaling. Circ Res 88: 129-131, 2001.
17. Fra AM, Williamson E, Simons K, and Parton RG. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci USA 92: 8655-8659, 1995.
18. Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, and Lisanti MP. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 24: 98-105, 2004.
19. Galbiati F, Razani B, and Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell 106: 403-411, 2001.
20. Galbiati F, Volonte D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG, and Lisanti MP. Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell 12: 2229-2244, 2001.
21. Ghitescu L and Bendayan M. Transendothelial transport of serum albumin: a quantitative immunocytochemical study. J Cell Biol 117: 745-755, 1992.
22. Gonzalez E, Nagiel A, Lin AJ, Golan DE, and Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J Biol Chem 279: 40659-40669, 2004.
23. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, and Pestell RG. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 275: 21203-21209, 2000.
24. Lipardi C, Mora R, Colomer V, Paladino S, Nitsch L, Rodriguez-Boulan E, and Zurzolo C. Caveolin transfection results in caveolae formation but not apical sorting of glycosylphosphatidylinositol (GPI)-anchored proteins in epithelial cells. J Cell Biol 140: 617-626, 1998.
25. Liu P, Rudick M, and Anderson RG. Multiple functions of caveolin-1. J Biol Chem 277: 41295-41298, 2002.
26. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, and Hu LR. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1061: 297-303, 1991.
27. Michel T and Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 100: 2146-2152, 1997.
28. Monier S, Dietzen DJ, Hastings WR, Lublin DM, and Kurzchalia TV. Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation or cholesterol. FEBS Lett 388: 143-149, 1996.
29. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, and Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA 92: 10339-10343, 1995.
30. Palade GE. Blood capillaries of the heart and other organs. Circulation 24: 368-388, 1961.
31. Palade GE. Role of plasmalemmal vesicles. In: The Lung: Scientific Foundations, edited by Cristal RG and West JB. New York: Raven, 1991.
32. Palade GE. Transport in quanta across the endothelium of blood capillaries (Abstract). Anat Rec 136: 254, 1960.
33. Predescu D, Horvat R, Predescu S, and Palade GE. Transcytosis in the continuous endothelium of the myocardial microvasculature is inhibited by N-ethylmaleimide. Proc Natl Acad Sci USA 91: 3014-3018, 1994.
34. Predescu D, Predescu S, and Malik AB. Transport of nitrated albumin across continuous vascular endothelium. Proc Natl Acad Sci USA 99: 13932-13937, 2002.
35. Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K, and Malik AB. Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol 289: L371-L381, 2005.
36. Predescu SA, Predescu DN, and Palade GE. Plasmalemmal vesicles function as transcytotic carriers for small proteins in the continuous endothelium. Am J Physiol Heart Circ Physiol 272: H937-H949, 1997.
37. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, and Lisanti MP. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 277: 8635-8647, 2002.
38. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
39. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, and Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682, 1992.
40. Schlegel A, Pestell RG, and Lisanti MP. Caveolins in cholesterol trafficking and signal transduction: implications for human disease. Front Biosci 5: D929-D937, 2000.
41. Schubert W, Frank PG, Razani B, Park DS, Chow CW, and Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 276: 48619-48622, 2001.
42. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, and Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 277: 40091-40098, 2002.
43. Shaul PW and Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol Lung Cell Mol Physiol 275: L843-L851, 1998.
44. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, and Michel T. Acylation targets endothelial nitric oxide synthase to plasmalemmal caveolae. J Biol Chem 271: 6518-6522, 1996.
45. Simionescu M and Simionescu N. Endothelial transport of macromolecules: transcytosis and endocytosis. A look from cell biology. Cell Biol Rev 25: 1-78, 1991.
46. Smart EJ, Ying Y, Donzell WC, and Anderson RG. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem 271: 29427-29435, 1996.
47. Smart EJ, Ying YS, Conrad PA, and Anderson RG. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol 127: 1185-1197, 1994.
48. Stan RV. Structure and function of endothelial caveolae. Microsc Res Tech 57: 350-364, 2002.
49. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, and McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101: 1401-1413, 1998.
50. Titheradge MA. The enzymatic measurement of nitrate and nitrite. In: Nitric Oxide Protocols, edited by Titheradge MA. Totowa, NJ: Humana, 1998, p. 83-93.
51. Van Meer G. Caveolin, cholesterol, and lipid droplets? J Cell Biol 152: F29-F34, 2001.
52. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG Jr, and Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968, 1998.
53. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, and Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.